Navigation Links
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Date:11/5/2013

PHILADELPHIA, Nov. 5, 2013 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA) stock between December 11, 2011 and October 31, 2013, inclusive. The investigation concerns whether Ariad and certain of its officers and/or directors disseminated materially false and misleading information to investors in violation of Sections 10(b), and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.

Ariad describes itself as an oncology company, focused on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer, and other difficult-to-treat cancers.  On October 9, 2013, Ariad disclosed that Iclusig, a drug the FDA approved in December, 2012 as a last-line treatment for certain kinds of chronic myeloid leukemia, had shown higher than expected rates of serious health problems related to blood clots. Two days later, the U.S. Food and Drug Administration announced it was investigating severe and life-threatening blood clots and narrowing of blood vessels in current patients taking the medication. On October 18, 2013 the Company announced it had agreed to terminate a trial of the drug in newly-diagnosed patients because arterial thrombotic events were observed in patients taking Iclusig. On October 31, 2013, at the FDA's request, the Company disclosed that it was suspending sales of the drug.

Upon its October 31, 2013, disclosure that it was suspending sales of Iclusig, Ariad shares declined $2.07 per share or over 30%, to close at $4.70 per share. As of November 4, 2013, Ariad's stock was trading at $2.98 per share, down 85 percent from its trading value before October 8, 2013.

If you wish to discuss what rights you may have related to a loss in your investment in Ariad or you have any information on Ariad's representations about the Iclusig drug, please contact Eduardo Texidor Jr. at etexidor@cprlaw.com or, toll free, at 1-888-375-7600. For those investors inquiring via email, please include "Ariad" in the subject line, and, in the body of the email, the number of shares purchased and your mailing address and telephone number.

Since 1973, Cohen, Placitella & Roth, PC has been recognized as one of the premier trial law firms in the country. The firm has extensive experience in prosecuting securities litigation involving violations of the federal securities laws, state law derivative actions and mergers and acquisitions cases, representing institutional investors such as public pension plans and union pension funds as well as individual shareholders suffering substantial investment losses due to corporate misconduct. LexisNexis Martindale-Hubbell® annually reports Cohen, Placitella & Roth's peer rating-the highest AV® - "a testament to professional excellence." Since the inauguration of its "Best Law Firms"' edition in 2010, U.S. News and World Report has annually listed Cohen, Placitella & Roth as one of the top-tier class action law firms in the country.

Contact:
Eduardo Texidor Jr.
Cohen, Placitella & Roth, PC
Toll free: 1-888-375-7600
etexidor@cprlaw.com


'/>"/>
SOURCE Cohen, Placitella & Roth, PC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
2. UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
3. Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence
4. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
7. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
8. Langland Collaboration with CISCRP to Show Participants How Their Words Can Impact a Clinical Trial
9. InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
10. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
11. French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Actinic Keratosis Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Keratosis epidemiology, Actinic Keratosis market valuations and ...
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
Breaking Medicine Technology:
(Date:5/6/2016)... LA (PRWEB) , ... May 06, 2016 , ... ... Health System and David Konur, CEO of Cardiovascular Institute of the South announced ... will be performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, ... communities and resources. Aging Life Care plays an important role as these professionals are ... Life Care is a holistic, client-centered approach to caring for older adults or others ...
(Date:5/5/2016)... ... 05, 2016 , ... The U.S. Food and Drug Administration ... to submit their products through an arduous federal approval process. The rules, which ... the market since February 15, 2007. That would essentially ban 99 percent of ...
(Date:5/5/2016)... ... , ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from ... Team Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and ... and Jason Moeschler, who’ll share pro tips with the injured veterans as they rip down ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has ... Every day, LELO fans reach out via email, social media and on the Volonté ... up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods are ...
Breaking Medicine News(10 mins):